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Abstract
Numerous factors can affect skeletal regeneration, including the extent of bone injury, mechanical loading, inflammation and
exogenous molecules. Bisphosphonates are anticatabolic agents that have been widely used to treat a variety of metabolic
bone diseases. Zoledronate (ZA), a nitrogen-containing bisphosphonate (N-BP), is the most potent bisphosphonate among the
clinicallyapprovedbisphosphonates.Casesofbisphosphonate-inducedosteonecrosisofthejawhavebeenreportedinpatients
receiving long term N-BP treatment. Yet, osteonecrosis does not occur in long bones. The aim of this study was to compare the
effects of zoledronate on long bone and cranial bone regeneration using a previously established model of non-stabilized tibial
fractures and a new model of mandibular fracture repair. Contrary to tibial fractures, which heal mainly through endochondral
ossification, mandibular fractures healed via endochondral and intramembranous ossification with a lesser degree of
endochondral ossification compared to tibial fractures. In the tibia, ZA reduced callus and cartilage formation during the early
stages of repair. In parallel, we found a delay in cartilage hypertrophy and a decrease in angiogenesis during the soft callus
phase of repair. During later stages of repair, ZA delayed callus, cartilage and bone remodeling. In the mandible, ZA delayed
callus,cartilageand boneremodelingin correlation withadecreaseinosteoclast number duringthesoftand hard callusphases
of repair. These results reveal a more profound impact of ZA on cartilage and bone remodeling in the mandible compared to
the tibia. This may predispose mandible bone to adverse effects of ZA in disease conditions. These results also imply that
therapeutic effects of ZA may need to be optimized using time and dose-specific treatments in cranial versus long bones.
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Introduction
Bisphosphonates (BP) are synthetic analogs of pyrophosphate
that can be incorporated in vivo into mineralized tissues [1]. Due
to their potent effects on osteoclastic bone resorption, BP are
widely used for the treatment and/or prevention of metabolic
bone diseases characterized by increased osteoclast activity such as
Paget’s disease, metastatic and osteolytic bone diseases, as well as
osteoporosis [2]. These anti-resorptive effects of BP are also
explored for improvement of callus strength and fracture healing
in combination with anabolic treatments [3]. There are two major
classes of bisphosphonates. The first group contains the less potent,
non-nitrogen containing BP that can be metabolized into
nonhydrolyzable analogues of ATP [4] and the second group
contains the more potent, nitrogen containing BP such as
alendronate, risedronate, and zoledronate (ZA). These potent
BPs interfere with the mevalonate biosynthetic pathway and
inhibit protein prenylation, which is important for osteoclast
function [2,5]. In 2002, intravenous ZA was approved to treat
patients with multiple myeloma and bone metastases. Although
ZA is the most effective BP in clinical use, undesirable effects have
been reported that require better understanding of its mechanisms
of action in bone. Cases of osteonecrosis of the jaw (ONJ) have
been reported in patients treated with high dose of nitrogen
containing bisphosphonates [6–8], but no reports were found in
long bones. As ONJ is often associated with implant procedures,
the bone repair process occurring around the implant is
considered a key event leading to bone necrosis. The adverse
effects of ZA could result from differences in mandibular and long
bone repair. Bones in the head and the appendicular skeleton are
derived from distinct cell lineages during embryonic development,
which may lead to differences in their regenerative capacities and
susceptibility to bisphosphonate treatment [9–11]. The goal of this
study was to contrast the impact of ZA on the repair of mandibular
and tibial fractures. We used a well-established model of non-
stabilized tibial fracture and created a mouse mandibular fracture
model to evaluate the effects of ZA on cranial versus long bone
repair at the cellular and molecular levels. Bisphosphonates may
not only act on osteoclast function but also on other cell types that
are required for a timely repair process including osteoblasts,
chondrocytes and endothelial cells [12,13]. Therefore, we assessed
the consequences of ZA treatment on cartilage and bone
formation within the fracture callus, as well as matrix remodeling,
osteoclasts and angiogenesis.
Materials and Methods
Zoledronate Treatment
All procedures followed protocols approved by the UCSF
Animal Care and Use Committee (approval number AN080353-
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e3177102B). Adult C57B6 wild type mice (males 3–4 month old) were
anesthetized with an intraperitoneal injection of 50 mg/ml
Ketamine/0.5 mg/ml Metedomidine (0.03 ml/mouse) and re-
ceived 3 mg (0.1 mg/kg) Zoledronate (ZA) (Zometa, Novartis
Pharma AG, Basel Switzerland) in 200 ml saline intravenously
once 4 weeks before fracture and once at the time of fracture. This
dosage is based on that which is typically used for treatment of
multiple myeloma or breast cancer in humans [7,14]. Control
mice received the same volume of saline solution intravenously.
Non-stabilized tibial fractures
Adult C57B6 wild type mice (males 3–4 month old) were
anesthetized with an intraperitoneal injection of 50 mg/ml
Ketamine/0.5 mg/ml Medetomidine (0.03 ml/mouse). Closed,
standardized non-stabilized fractures were produced in the mid-
diaphysis of the right tibia via three point bending as previously
described [15] (Fig. 1). Mice were sacrificed by cervical dislocation
following an intraperitoneal injection of 2% Avertin (0.5 ml/
mouse) and fracture calluses were collected at 5, 7, 10, 14, 21 and
28 days post-fracture (n=5 per group). Mandibular and tibial
fractures were induced in two separate groups of animals.
Non-stabilized mandibular fractures
Adult C57B6 wild type mice (males 3–4 month old) were
anesthetized with an intraperitoneal injection of 50 mg/ml
Ketamine/0.5 mg/ml Medetomidine (0.03 ml/mouse) and re-
ceived a preoperative dose of antibiotic (cefazolin, 10 mg/kg). For
non-stabilized mandibular fractures, an incision was made along
the inferior portion of the right hemimandible, and the masseter
muscle was divided along its length and elevated to expose the
body of the mandible bone. Five holes were created using a high-
speed dental drill filled with an insect-pin along the mandible bone
Figure 1. Effects of Zoledronate on the course of tibial fracture repair. (A) Sections through the calluses (green dashed-lines) of PBS- (left)
and zoledronate- (right) treated mice were stained with Safranin-O/Fast Green (days 7, 10 and 14 post-fracture) to detect cartilage (arrowsheads) and
Trichrome (days 21 and 28 post-fracture) to detect bone (arrows). White arrows indicate the fracture site. Scale bar=500 mm. (B) Histomorphometric
analyses of total callus volume (Top), total cartilage volume (CV, middle) and total bone volume (BV, bottom) on PBS treated and ZA treated-mice at
days 7, 10, 14, 21 and 28 post-fracture (n=6 per group). *p,0.05, **,0.01. Bars represent mean6s.d.
doi:10.1371/journal.pone.0031771.g001
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bone (Fig. 2). Fracture was created using surgical tweezers. After
creating the fracture, the soft tissues and skin were closed and
animals were given analgesics. All animals were fed with soft diet
for at least 7 days. All animals received a subcutaneous injection of
buprenorphine (1.0 mg/kg) for analgesia immediately after
Figure 2. Mandibular fracture model and effects of zoledronate on the course of mandibular fracture repair. (A) To create a
mandibular fracture, the skin was opened and the mandible was exposed (left). Five holes were drilled (black arrow) and the fracture was created
(white arrow) by surgical tweezers. (B) Sections through the PBS- (left) and zoledronate- (right) treated calluses (green dashed-lines) were stained with
Safranin-O/Fast Green (day 7 and day 10 post-fracture) to detect cartilage (arrowheads) and Trichrome (day 14, 21, and 28 post-fracture) to detect
bone (arrows). White arrows indicate the fracture site. Scale bar=500 mm. (C) Histomorphometric analyses of total callus volume (TV, Top), total
cartilage volume (CV, middle) and total bone volume (BV, bottom) on PBS treated and zoledronate treated-mice at days 7, 10, 14, 21 and 28 post-
fracture (n=6 per group). *p,0.05, **,0.01. Bars represent mean6s.d.
doi:10.1371/journal.pone.0031771.g002
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activity were monitored frequently. Mice were sacrificed by
cervical dislocation following an intraperitoneal injection of 2%
Avertin (0.5 ml/mouse) and fracture calluses were collected at 5,
7, 10, 14, 21 and 28 days post-fracture (n=5 per group).
Histological and histomorphometric analyses of cartilage
and bone
Callus tissues were fixed overnight at 4uC in 4% paraformal-
dehyde, decalcified at 4uC in 19% EDTA (pH 7.4) for 10–14 days,
then dehydrated in a graded ethanol series and embedded in
paraffin. Serial sections (10 mm thick) were collected throughout
the entire callus and analyzed by histomorphometry as previously
described [15–17]. To determine the amount of cartilage within
each callus, every thirtieth section was stained with Safranin-O/
Fast Green. To determine the amount of bone, adjacent sections
were stained with Milligan’s Trichrome. Images were captured
from a Leica DM 5000 B light microscope (Leica Microsystems
GmbH) that was equipped with a camera (Diagnostic). The area of
callus, cartilage and bone was determined using Adobe Photo-
Shop.
Immunohistochemistry
Representative sections were processed for immmunohisto-
chemistry. Briefly, after deparaffinization and hydration, antigen
retrieval was performed by incubating with 0.05% trypsin and
followed by 3% H2O2 in methanol for 15 min to inhibit
endogenous peroxidase activity. Slides were treated with 1.5%
donkey serum or 1.5% goat serum as indicated by manufacturer’s
instruction (goat or rabbit ABC staining kit; Santa Cruz
Biotechnology, Santa Cruz, CA). Sections were incubated with
the primary antibody (affinity purified goat polyclonal antibody
against Collagen type II, Santa Cruz Biotechnology, CA; affinity
purified rabbit polyclonal antibody against Collagen type X,
Chemicon, Millipore, Billerica, MA) diluted (1:50) in the blocking
serum in a humidified chamber at 4uC overnight. Control sections
were incubated with normal goat IgG or normal rabbit IgG
serums. Detection of primary antibody binding was done using
goat or rabbit ABC staining kit (Santa Cruz Biotechnology, Santa
Cruz, CA). Sections were developed with DAB and counterstained
with 1% Fast Green.
Detection and quantification of osteoclasts in the
fracture callus
Tartrate-resistant acid phosphatase (TRAP) staining was
performed using a leukocyte acid phosphatase kit (Sigma) on
serial sections (10 mm) that were 300 mma p a r tt h r o u g ht h e
callus. The number of osteoclasts within the fracture callus was
estimated using an Olympus CAST system (Olympus) and
software by Visiopharm (Visiopharm) as previously described
[18]. Briefly, fracture callus was outlined using low magnifica-
tion in each section. Ten to twenty fields that covered
approximately 10% of the fracture callus were systematically
acquired using unbiased uniform random sampling under
higher magnification. A counting frame probe was also selected
to quantify the number of osteoclasts and the area of the callus
within each field. Values are expressed as number of osteoclasts
per mm
2 callus tissue.
Detection and quantification of apoptotic cells and
osteoclasts in the fracture callus
To detect osteoclasts and apoptotic cells, TUNEL assay to
detect DNA fragmentation was performed using a TUNEL kit
(ApopTag, Millipore) according to the manufacturer’s instructions
followed by TRAP staining. The number of apoptotic cells and
osteoclasts within the fracture callus was estimated on three center
sections using an Olympus CAST system (Olympus) and software
by Visiopharm (Visiopharm) as described above.
Detection and quantification of tissue vascularity in the
fracture callus
To visualize and quantify blood vessels at day 5 post-fracture,
calluses were cryo-embedded in OCT. Serial sections (10 mm) that
were 600 mm apart were selected throughout the callus and
immunohistochemistry using an anti-platelet endothelial cell
adhesion molecules (PECAM) antibody was performed [15]. For
each sample, six sections were analyzed. The length density (length
of blood vessels per unit volume of the reference space) of the
blood vessels within the fracture callus and the surface density
(area of the outer surface of blood vessels per unit volume of the
reference space) of the blood vessels within the fracture callus were
estimated using an Olympus CAST system (Olympus) and
Visiopharm software (Visioplarm) as previously described
[18,19]. The whole callus was used as the reference space and
its volume was estimated using Calvalieri’s Principle [20,21].
Statistical analyses
The student t-test was used to compare experimental and
control samples, and p-values of ,0.05 were considered
significant.
Results
Zoledronic Acid affects the formation and remodeling of
cartilage and bone during tibial fracture repair
To examine the long-term effects of ZA on healing of non-
stabilized tibial fractures, we injected ZA intravenously 4 weeks
before fracture and on the day of fracture. We chose a high dose of
ZA as used in cancer patients and delivered two doses in order to
maximize the incorporation of ZA within bone prior to injury
[7,14]. Histological analyses showed a delay in fracture repair in
ZA-treated mice (Fig. 1A). There was less cartilage during the soft
callus phase of repair (day 7 to 10 post-fracture) in ZA-treated
compared to PBS-treated mice as shown by Safranin-O staining
(Fig. 1A). Trichrome staining did not reveal an apparent delay in
bone deposition within the callus until day 14 (data not shown).
However, there was more woven bone in the callus of ZA treated
mice by day 28, indicating a delay in the restoration of the bone
marrow cavity (Fig. 1A). Histomorphometric analyses showed that
total callus volume was smaller in ZA-treated samples compared to
controls at day 7. Total callus volume gradually increased from
day 7 to 14 and was reduced by day 28 post-fracture in control
samples, while it remained high by day 28 in ZA-treated samples
indicating a delay in callus formation and remodeling (Fig. 1B,
top). Histomorphometric analyses confirmed that there was
significantly less cartilage in the callus of ZA-treated samples at
days 7 and 10 post-fracture (Fig. 1B, middle). Cartilage volume
peaked by day 10 and decreased by day 14 in PBS-treated
samples, while cartilage volume remained high by day 14
compared to day 10 in ZA-treated samples (Fig. 1B, middle).
These results indicate that ZA delays both cartilage deposition and
remodeling during tibial fracture repair. Bone volume was
significantly higher by day 10 post-fracture and remained high
by day 28 in ZA-treated samples compared to controls implying an
increase in bone deposition during the soft callus phase of repair
followed by a delay in bone remodeling (Fig. 1B, bottom).
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during non-stabilized mandibular fracture repair
To compare the effects of ZA on tibial and mandibular fracture
repair, we developed a non-stabilized mandibular fracture model.
Fractures were created from the top of the coronoid process to the
gonial angle of mandible bone (Fig. 2A). Histological analyses
showed that mandibular fractures healed via endochondral
ossification with a lesser degree of cartilage deposition compared
to non-stabilized tibial fractures (Fig. 2B). Callus size was smaller
in mandibular compared to tibial fractures. As observed in tibial
fractures, mandible fracture calluses were filled with woven bone
by day 14 post-fracture, and gradually resorbed and bridged by
day 21. Bone remodeling was well underway by day 28 (Fig. 2B,
left). Histomorphometric analyses confirmed these histological
analyses. Total callus volume peaked at day 10 and gradually
reduced by day 28 post-fracture in PBS- and ZA-treated samples,
but the total callus volume was significantly greater in ZA-treated
samples compared to the controls at days 14 and 21 post-fracture
indicating that there was a delay in callus remodeling (Fig. 2C,
top). Cartilage formed by day 7, peaked at day 10 and decreased
by day 14, but cartilage volume remained significantly high in ZA-
treated calluses compared to PBS-treated calluses. Cartilage was
completely resorbed by day 21 in both ZA- and PBS-treated
calluses (Fig. 2C, middle). Bone volume gradually increased from
day 7 to day 14 and decreased by day 28 in PBS-treated calluses,
but remained high from day 14 to day 28 in ZA-treated calluses
(Fig. 2C, bottom). These data indicate a delay in cartilage and
bone remodeling in the repair of non-stabilized mandible fractures
treated with ZA.
Zoledronic acid delays cartilage hypertrophy during tibial
fracture healing
Since cartilage formation was delayed in tibial but not in
mandibular fracture healing, we performed immunohistochemis-
try to examine chondrocyte differentiation following ZA and PBS
treatment. In tibial fracture calluses, immunostaining for collagen
type II was detected in chondrocytes of both PBS and ZA-treated
mice by day 5 post-injury (Fig. 3A, B). However, collagen type X
immunostaining was observed in PBS but not in ZA-treated
calluses (Fig. 3D, E). By day 10, collagen type X was expressed in
both groups (Fig. 3F and data not shown), therefore cartilage
hypertrophy was delayed during tibial fracture repair as a result of
ZA treatment. In mandibular fracture calluses, immunostaining
for collagen type II was markedly decreased compared to tibial
fractures (Fig. 3G, H), which was in concordance with decreased
cartilage formation reported via histology and histomorphometry.
Immunostaining for collagen type X was seen in the calluses of
PBS and ZA-treated mice at days 5 and 10 post-fracture (Fig. 3J,
K, L and data not shown).
Zoledronic acid reduces osteoclastogenesis during
mandibular fracture healing
Callus formation and remodeling involves the deposition and
breakdown of extracellular matrix by the coordinated action of
osteoblasts, chondrocytes and osteoclasts. Osteoclasts are a well-
known target of bisphosphonates action. Therefore, we investigat-
ed the effects of ZA on osteoclast numbers in tibial and
mandibular fractures. There were no significant differences in
the number of TRAP-positive cells per callus area between ZA-
treated and control samples in tibial fractures, but there were less
TRAP-positive cells per callus area in ZA-treated samples
compared to the controls in mandibular fractures at both days 7
and 14 post-fracture (Fig. 4). To assess whether the decrease in the
number of TRAP-positive cells was due to apoptosis, we
performed double staining for TUNEL and TRAP at day 5
post-fracture. Overall there was minimal cell death in the callus of
both tibial and mandibular fractures, and we did not observe
significant differences between ZA-treated and control groups
(data not shown). Dead cells were found at the fracture site, within
the bone marrow and in the cortex, while TRAP-positive cells
were found primarily around new bone adjacent to the periosteum
and within the fracture callus (Fig. 5 and data not shown). Double
staining and quantitative analyses showed that TRAP-positive cells
were not TUNEL-positive, suggesting that ZA treatment did not
induce osteoclast cell death (Fig. 5 and data not shown). Therefore,
the decrease in the number of TRAP-positive cells were not due to
increase cell death in mandibular fractures.
Zoledronic acid reduces angiogenesis in the tibial
fracture callus
Skeletal tissue deposition and remodeling is tightly linked with
revascularization of the fracture site. To examine whether ZA
affects vascularization, we quantified blood vessel length and
surface densities in ZA- and PBS-treated calluses. Immunohisto-
Figure 3. Effects of Zoledronate on collagen types II and X
expression during tibial and mandibular fracture repair.
Immunostaining of collagen type II (A–B, G–H, black arrows) and
collagen type X (D–F, J–L, white arrows) near the periosteum within
tibial (top) and mandibular (bottom) fracture calluses of PBS (left) and
zoledronate (middle and right) treated mice. No staining is observed in
negative controls (C and I).
doi:10.1371/journal.pone.0031771.g003
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that blood vessel length density (Fig. 6B) and surface density
(Fig. 6C) were significantly reduced in ZA-treated calluses
compared to controls in tibial fractures but not in mandibular
fractures at day 5 post-fracture. Our results also revealed that in
the absence of ZA treatment, blood vessel length density and
surface density were significantly higher in tibial fractures
compared to mandibular fractures (Fig. 6).
Discussion
Differences between tibial and mandibular fracture repair
In this study, we investigated the differences in healing between
cranial and long bones and the responses to ZA treatment in these
two repair sites. We created a non-stabilized mandibular fracture
model to compare healing with our previously described model of
non-stabilized tibial fractures [15,22]. While non-stabilized tibial
fractures heal mostly through endochondral ossification, we show
that non-stabilized mandibular fractures heal through intramem-
branous and endochondral ossification with a reduced amount of
endochondral ossification compared to tibial fractures. Differences
between tibial and mandibular fracture repair may be due to
differences in their mechanical environment [22,23]. Previous
studies in our laboratory showed that tibial fractures heal via
intramembranous ossification when a rigid fixation is applied to
the fracture site, thus indicating that the mechanical environment
influences the mode of repair [15,22]. In the absence of
mechanical stimuli, mesenchymal cells differentiate directly into
osteoblasts but under the influence of mechanical stimuli cells can
differentiate into osteoblasts and chondrocytes [22]. Mechanical
stimuli also play a significant role in bone repair by regulating
vascular growth [24,25]. VEGF and TGF-beta are released from
human fracture hematoma with mechanical loading [24]. In our
study both tibias and mandibles were loaded. However, the
mechanical stimuli and stress are presumably greater in the tibia
due to weight bearing, which may explain the increase in callus
size, number of blood vessels and degree of endochondral
ossification compared to mandibular fractures.
Differences in the extent of endochondral ossification between
tibial and mandibular fracture calluses may also be due to the
distinct cell populations that participate in repair. Bones in the
head and the trunk do not share the same embryonic origins. Long
bones in the limb are derived from the trunk lateral plate
mesoderm and form via endochondral ossification, while the
mandible is derived from the paraxial mesoderm in the head, and
forms via intramembranous ossification [10]. We previously
showed that skeletal progenitor cells are recruited from the local
periosteum during long bone repair [26]. Other reports indicate
that cells in the mandible are recruited locally during repair [27].
Given the distinct embryonic origins of cells that constitute the
mandible and the tibia, progenitor cells in the mandible may be
more prone to undergo bone formation via intramembranous
ossification while cells in the tibia may be more prone to undergo
endochondral ossification. Yet it is interesting to note that both
tibia and mandible can form bone via endochondral ossification in
a non-stable mechanical environment and via intramembranous
ossification in a stable mechanical environment. Regardless of the
source of cells, the mechanical environment largely influences cell
fate after bone injury. These fundamental differences between
tibial and mandibular fractures may in part explain the differential
Figure 4. Effects of zoledronate on osteoclastogenesis during
tibial and mandibular fracture repair. Stereological analyses of
TRAP positive cells per area of fracture callus (n=6 per group) in PBS-
and zoledronate-treated mice at day 7 (A) and day 14 (B) post-fracture.
**p,0.01. Bars represent mean6s.d.
doi:10.1371/journal.pone.0031771.g004
Figure 5. Effects of zoledronate on apoptosis during tibial and
mandibular fracture repair. TUNEL and TRAP double staining on ZA-
treated tibial (A and B) and mandibular (C–E) fractures at day 5 post-
injury. High magnifications (B, D, E) indicate apoptotic cells (black
arrows) and TRAP-positive cells (white arrows) within the fracture callus.
No TRAP-positive apoptotic cells can be detected at the fracture site. (A,
C) Scale bar=50 mm; (B, D, E) Scale bar=10 mm.
doi:10.1371/journal.pone.0031771.g005
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skeletal progenitors within cranial and long bones may not have
the same sensitivity to ZA, thus leading to direct effects on
osteoblasts and/or chondrocytes. On the other hand, indirect
effects of ZA may be due to the distinct mechanical environments
and effects on other cell types such as osteoclasts and endothelial
cells.
Site-specific effects of Zoledronic Acid in late stages of
fracture repair
Although ZA does not prevent fracture healing, we observed
significant changes during healing of mandible and tibial fractures
as a consequence of ZA treatment. This was not due to an
insufficient dosage of ZA since we maximized the dosage based on
that used in cancer therapies [7,14]. We show that intravenous ZA
injection increases the callus size and bone volume during the
remodeling phase of both mandibular and tibial fracture repair.
This is consistent with previous studies, which reported that ZA
treatment delays bone remodeling and simultaneously increases
the strength of the callus during late stages of fracture repair [28].
In addition, we report a delay in cartilage remodeling, suggesting
that ZA affects matrix-remodeling in both cartilage and bone.
Interestingly, we observed a more severe remodeling defect in
mandibular compared to tibial fractures, which was linked to a
decrease in the number of osteoclasts in the ZA treated mandibles.
This decrease in osteoclast number was not due to increased cell
death, and may therefore result from a decrease in the infiltration
of osteoclasts in the callus [29–31]. This more pronounced
remodeling defect in the mandible may also result from impaired
osteoclast function [30]. Compared to long bones, osteoclasts in
cranial bones exhibit higher levels of proteolytic enzymes and
resorptive activities, which may augment their sensitivity to ZA
treatment [32,33].
Site-specific effects of Zoledronic Acid in early stages of
fracture repair
Previous studies on the effect of bisphosphonates on fracture
healing mostly focused on later stages of repair, where they induce
a delay in callus remodeling both in stabilized and non-stabilized
mechanical environments [34–36]. Our study reveals the effects of
ZA in the early stages of bone repair and the process of
endochondral ossification. We treated mice starting one month
prior to the injury in order to specifically assess long-term effects of
ZA and the impact on the initial stages of repair. There was a
decrease in callus size and cartilage volume in the early soft callus
phase of tibial fracture repair, but this effect was not seen in
mandibular fractures. In parallel, ZA delayed chondrocyte
hypertrophy in tibial but not mandibular fractures. A direct effect
of ZA on chondrogenesis may be more apparent in tibial factures
due to increased cartilage volume and higher degree of
endochondral ossification. Concurrently, we detected a decrease
in angiogenesis in tibial fractures treated with ZA compared to
control groups. Impaired angiogenesis could result from delayed
hypertrophy and delayed VEGF expression in cartilage. Several
studies reported that bisphosphonates interfere with the angio-
genic process through various molecular pathways [37–41]. This
delay in re-vascularisation of the fracture site might also affect
cartilage formation. Indeed, we have previously observed a
correlation between low blood vessel density and inhibition of
chondrogenesis during the initial phase of stabilized fracture repair
[19]. In parallel, we observed early anabolic effects on bone, which
can be attributed to stimulatory effects on osteoblast proliferation
in vitro [42–45].
Figure 6. Effects of zoledronate on angiogenesis during tibial
and mandibular fracture repair. (A) PECAM immunostaining (black
arrows) on PBS- (top) and ZA-treated (bottom) tibial (left) and
mandibular (right) fracture calluses. Scale bar=200 mm. (B) Analysis of
the length density of blood vessels within the callus (mm/mm
3) and (C)
analysis of the surface density of blood vessels within the callus (mm
2/
mm
3) in PBS- and zoledronate-treated mice at day 5 post-fracture (n=6
per group). *p,0.05. Bars represent mean6s.d.
doi:10.1371/journal.pone.0031771.g006
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versus long bone repair in mice. The soft callus phase of repair was
more affected in the tibia compared to the mandible with a delay
in cartilage and bone deposition, in cartilage hypertrophy and
angiogenesis. ZA had a more profound impact on tissue
remodeling in mandibular compared to tibial fractures, which
was correlated with a decrease in osteoclasts. These site-specific
effects of ZA do not necessarily explain the occurrence of ONJ,
since other factors are involved such as infection, combined
treatment with corticosteroids, immunosuppressive agents or
chemotherapy [46–48]. These results suggest that BP can be used
as anticatabolic agents to augment bone repair with or without
combination with anabolic agents [3,28], however, the dosage and
the timing of anti-resorptive therapy to augment the size and
strength of the callus may change depending on the type of bone
and the mechanical environment.
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